Results 11 to 20 of about 4,014 (178)

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2023
Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Mohammad Ashraf Bhat, Aadil Nabi Mir, Manzoor Ahmad Parry, Irshad Ahmad Parray   +3 more
doaj   +2 more sources

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 2 approved] [PDF]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +4 more sources

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure

Drug Design, Development and Therapy, 2017
Fazia Mir, Alp S Kahveci, Jamal A Ibdah, Veysel Tahan Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA Abstract: Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide ...
Mir F, Kahveci AS, Ibdah JA, Tahan V
doaj   +1 more source

Efficacy of Sofosbuvir/Velpatasvir (SOF/VEL) Combination in Children with chronic Hepatitis C: A Prospective Study

Pakistan Armed Forces Medical Journal
Objective: To evaluate the efficacy and safety of Sofosbuvir/Velpatasvir (SOF/VEL) combination therapy in children aged 3–12 years with chronic hepatitis C (CHC). Study Design: Prospective analytical study. Place and Duration of Study: Department of
Samina Khan, Farooq Ikram, Saadiya Mushtaq, Husna Khan, Ifnan Shamraiz, Adnan Shahzad   +5 more
doaj   +2 more sources

Real-World Effectiveness and Safety of Sofosbuvir-Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre Study. [PDF]

J Viral Hepat
ABSTRACT Few direct‐acting antiviral regimens are approved in China for children and adolescents with chronic hepatitis C virus (HCV) infection and data are limited on their efficacy and safety in this population. This retrospective, multi‐centre study aimed to assess the real‐world effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF) and ...
Liu L, Li M, Zhu S, Dong Y, Zu H, Yu P, Liu R, Chen Y, Lin J, Gustafson C, Ramroth H, Liu L, Luo Y.   +12 more
europepmc   +2 more sources

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection [PDF]

, 2017
BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We
Bansal, Meena B, Michael P. Manns, Stephen Pianko, Younes, Ziad, Mchutchison, John, G., Landis, Charles, S, Natarajan Ravendhran, Robert H. Hyland, Flamm, Steven L, Cooper, Curtis, Younes, Ziad H, Tran, Tram, Curry, Michael, Tran, Tram T, Manns, Michael, Huang, K.C., Huang, K C, Reddy, K R, Schiff, Eugene, Curtis L. Cooper, Jie Zhang, Brainard, Diana M, Simone I. Strasser, Michael P. Curry, Steven L. Flamm, Pianko, Stephen, Svarovskaia, Evguenia, Charles S. Landis, Peter Buggisch, Buggisch, Peter, Diana M. Brainard, G. Mani Subramanian, Stamm, Luisa, Stuart C. Gordon, Marc Bourlière, Zhang, Jie, Flamm, Steven, L., Kowdley, Kris, V., John G. McHutchison, Bourlière, Marc, Ravendhran, Natarajan, Hadas Dvory-Sobol, Curry, Michael P, Stefan Zeuzem, Luisa M. Stamm, Brainard, Diana, K. Rajender Reddy, Tram T. Tran, Eugene R. Schiff, Alnoor Ramji, Evguenia Svarovskaia, McHutchison, John G, Vierling, John, Ramji, Alnoor, Reddy, K. Rajender, Subramanian, G. Mani, Kris V. Kowdley, Subramanian, G M, Cooper, Curtis L, Dvory-Sobol, Hadas, Hyland, Robert, John M. Vierling, Huang, K.C, Verna, Elizabeth C, Strasser, Simone I, Bansal, Meena, Victor de Lédinghen, K.C. Huang, de Lédinghen, Victor, Landis, Charles S, Elizabeth C. Verna, Subramanian, G Mani, Hyland, Robert H, Stamm, Luisa M, Gordon, Stuart, Myron Tong, Meena B. Bansal, Ziad H. Younes, Kowdley, Kris V, Reddy, K Rajender, Gordon, Stuart C, Strasser, Simone, Verna, Elizabeth, Manns, Michael P, Tong, Myron, Schiff, Eugene R, Vierling, John M, Zeuzem, Stefan   +87 more
core   +3 more sources

Successful treatment of vertically acquired Hepatitis C in a child using direct-acting antiviral therapy administered via gastrojejunal tube: A case report. [PDF]

JPGN Rep
Abstract Hepatitis C virus (HCV) remains a significant global health burden, with vertical transmission being the primary route of infection in children. Direct‐acting antivirals (DAAs) have transformed HCV treatment in pediatrics, but limited data exist on their administration in medically complex children who are dependent on enteral tubes. We report
Chen C, Gibson L, Squires J.
europepmc   +2 more sources

Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial [PDF]

J Viral Hepat
ABSTRACT The introduction of potent, well‐tolerated direct‐acting antivirals (DAAs) has transformed hepatitis C virus (HCV) therapy and spurred global elimination efforts. However, the extensive genetic diversity of HCV may affect antiviral efficacy, particularly in low and middle‐income regions where limited data currently exist.
Han W, Solomon S, Wagner‐Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D.   +10 more
europepmc   +2 more sources

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

Journal of Education, Health and Sport, 2023
Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram, Patryk Banaś, Justyna Adamus, Jakub Rafał Pierzchała, Katarzyna Bednarz, Natalia Sobańska, Aleksandra Paulina Banasiak, Rafał Teichman, Jakub Kasprowicz, Michał Hyjek   +9 more
doaj   +1 more source

Molecular docking analysis of peptide-based antiviral agents against SARS-CoV-2 main protease: an approach towards drug repurposing

Exploration of Medicine, 2023
Aim: Utilizing the therapeutic potentials of previously approved medications against a new target or pharmacological response is known as drug repurposing.
Abhishek Chaurasiya, Abhimannu Shome, Pooja A. Chawla   +2 more
doaj   +1 more source